#1 Clinical Trials Search in Europe

[N-{(4R)-4-Carboxy-Κo-4-[4,7,10-Tris(Carboxy-Κ3O4,O7,O10-Methyl)-1,4,7,10-Tetraazacyclododecan-1-Yl-Κ4N1,N4,N7,N10]Butanoyl}-3-Iodo-D-Tyrosyl-D-Phenylalanyl-N6-(8-{N2-[(L-Glutamic Acid-N-Yl)Carbonyl]-L-Lysin-N6-Yl}-8-Oxooctanoyl)-D-Lysinato(3−)](177Lu)Lutetium

A clinical trial is underway to evaluate the effectiveness of 177Lu-PNT2002, a new radioactive drug, in treating metastatic castration-resistant prostate cancer (mCRPC). This phase 3 study, known as SPLASH, compares 177Lu-PNT2002 to standard hormonal therapies like abiraterone or enzalutamide in patients who have progressed after initial hormone treatment. The trial aims to determine if 177Lu-PNT2002 can delay cancer progression and improve overall survival in these patients.

Table of Contents

What is 177Lu-PNT2002?

177Lu-PNT2002 is an innovative medication being studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is classified as a PSMA-targeted radioligand therapy. This means it combines a molecule that specifically targets prostate cancer cells with a radioactive element (Lutetium-177) to deliver targeted radiation therapy[1].

The full chemical name of this drug is quite complex: [N-{(4R)-4-CARBOXY-ΚO-4-[4,7,10-TRIS(CARBOXY-Κ3O4,O7,O10-METHYL)-1,4,7,10-TETRAAZACYCLODODECAN-1-YL-Κ4N1,N4,N7,N10]BUTANOYL}-3-IODO-D-TYROSYL-D-PHENYLALANYL-N6-(8-{N2-[(L-GLUTAMIC ACID-N-YL)CARBONYL]-L-LYSIN-N6-YL}-8-OXOOCTANOYL)-D-LYSINATO(3−)](177LU)LUTETIUM. However, for simplicity, it’s referred to as 177Lu-PNT2002 in clinical settings[1].

Medical Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer. In this condition:

  • Metastatic means the cancer has spread beyond the prostate to other parts of the body.
  • Castration-resistant means the cancer continues to grow even when the levels of male hormones (androgens) are reduced to very low levels in the body.

This type of cancer is typically challenging to treat, as it has become resistant to standard hormone therapy treatments[1].

How 177Lu-PNT2002 Works

177Lu-PNT2002 works by targeting a specific protein called Prostate-Specific Membrane Antigen (PSMA), which is often found in high amounts on prostate cancer cells. The medication consists of two main parts:

  1. A molecule that seeks out and attaches to PSMA on cancer cells.
  2. A radioactive element (Lutetium-177) that delivers radiation directly to these cancer cells.

This targeted approach aims to destroy cancer cells while minimizing damage to healthy tissues[1].

Clinical Trial Overview: The SPLASH Study

177Lu-PNT2002 is currently being evaluated in a Phase 3 clinical trial called the SPLASH study. This study aims to compare the effectiveness of 177Lu-PNT2002 against standard treatments (abiraterone or enzalutamide) in patients with mCRPC who have progressed after initial hormone therapy[1].

Key aspects of the SPLASH study include:

  • Randomization of patients into two groups: one receiving 177Lu-PNT2002 and the other receiving either abiraterone or enzalutamide.
  • The main goal is to see if 177Lu-PNT2002 can delay the progression of cancer compared to standard treatments.
  • The study will also look at overall survival, cancer response rates, and safety of the treatment.

Potential Benefits of 177Lu-PNT2002

Based on the objectives of the SPLASH study, 177Lu-PNT2002 may offer several potential benefits for patients with mCRPC[1]:

  • Delayed cancer progression
  • Improved overall survival
  • Better response rates compared to current treatments
  • Reduced risk of symptomatic skeletal events (complications related to bone metastases)
  • Potential improvements in PSA levels (a blood marker for prostate cancer)

Eligibility Criteria for the SPLASH Study

To participate in the SPLASH study, patients must meet certain criteria. Some key eligibility requirements include[1]:

  • Male, aged 18 years or older
  • Confirmed diagnosis of metastatic castration-resistant prostate cancer
  • Previous progression on one type of hormone therapy
  • Positive PSMA-PET scan
  • Adequate organ function
  • No prior chemotherapy for castration-resistant prostate cancer
  • No prior treatment with PSMA-targeted radioligand therapy

It’s important to note that these are just some of the criteria, and a healthcare provider would need to do a full assessment to determine eligibility.

Safety Considerations

As with any medical treatment, 177Lu-PNT2002 may have potential side effects. The SPLASH study is carefully monitoring the safety of this treatment. Some areas of focus include[1]:

  • Frequency and severity of adverse events
  • Changes in physical exam findings, vital signs, and laboratory values
  • Effects on heart function
  • Potential impacts on bone marrow, liver, and kidney function

Patients in the study will be closely monitored for any side effects or safety concerns.

Conclusion

177Lu-PNT2002 represents a promising new approach in the treatment of metastatic castration-resistant prostate cancer. By targeting cancer cells specifically and delivering radiation directly to them, this therapy aims to offer improved outcomes for patients with this challenging form of prostate cancer. The ongoing SPLASH clinical trial will provide crucial information about the effectiveness and safety of this treatment compared to current standard therapies[1].

If you have mCRPC and are interested in learning more about 177Lu-PNT2002 or the SPLASH study, it’s important to discuss this with your healthcare provider. They can provide more information and help determine if this treatment option might be suitable for your specific situation.

Aspect Details
Study Name SPLASH (Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment)
Drug Tested 177Lu-PNT2002
Condition Metastatic castration-resistant prostate cancer (mCRPC)
Trial Phase Phase 3
Main Objective To determine the efficacy of 177Lu-PNT2002 versus abiraterone or enzalutamide in delaying radiographic progression
Primary Endpoint Radiological progression-free survival (rPFS)
Key Eligibility Criteria Male, 18+ years, mCRPC, progressed on previous ARAT therapy, PSMA-PET scan positive
Treatment Arms 177Lu-PNT2002 vs. Enzalutamide/Abiraterone (2:1 randomization)
Dosing Up to 6.8 GBq per dose, max total 27.2 GBq over 24 weeks
Follow-up Period At least 5 years from first treatment dose

FAQ

  • What is 177Lu-PNT2002 and how does it work? 177Lu-PNT2002 is a radioactive drug that targets prostate-specific membrane antigen (PSMA), a protein found on prostate cancer cells. It delivers radiation directly to cancer cells, potentially killing them while minimizing damage to healthy tissue.
  • Who is eligible for this clinical trial? The trial is for men aged 18 or older with metastatic castration-resistant prostate cancer who have progressed on previous hormone therapy. Patients must have a positive PSMA-PET scan and meet specific health criteria.
  • How is the treatment administered? 177Lu-PNT2002 is given as an intravenous injection. Patients receive up to 6.8 GBq (gigabecquerels) per dose, with a maximum total dose of 27.2 GBq over 24 weeks.
  • What are the main goals of the SPLASH trial? The primary goal is to measure how long patients live without their cancer getting worse (radiological progression-free survival). Secondary goals include assessing tumor response, overall survival, and safety of 177Lu-PNT2002 compared to standard hormone therapies.
  • What happens if a patient's cancer progresses during the trial? Patients in the control group (receiving abiraterone or enzalutamide) who experience cancer progression may be eligible to cross over and receive 177Lu-PNT2002 treatment, if they meet certain criteria.

Ongoing Clinical Trials on [N-{(4R)-4-Carboxy-Κo-4-[4,7,10-Tris(Carboxy-Κ3O4,O7,O10-Methyl)-1,4,7,10-Tetraazacyclododecan-1-Yl-Κ4N1,N4,N7,N10]Butanoyl}-3-Iodo-D-Tyrosyl-D-Phenylalanyl-N6-(8-{N2-[(L-Glutamic Acid-N-Yl)Carbonyl]-L-Lysin-N6-Yl}-8-Oxooctanoyl)-D-Lysinato(3−)](177Lu)Lutetium

  • Study on Treating Metastatic Castration-Resistant Prostate Cancer with 177Lu-PNT2002 Compared to Abiraterone or Enzalutamide for Patients After Hormonal Therapy

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands Sweden

Glossary

  • Metastatic castration-resistant prostate cancer (mCRPC): A type of advanced prostate cancer that has spread to other parts of the body and continues to grow despite treatments that lower testosterone levels.
  • PSMA-PET scan: A specialized imaging test that uses a radioactive tracer to detect prostate cancer cells throughout the body.
  • Radiological progression-free survival (rPFS): The length of time during and after treatment that a patient lives without their cancer getting worse, as determined by imaging scans.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • PCWG3: Prostate Cancer Working Group 3, guidelines for designing and conducting clinical trials for prostate cancer treatments.
  • Androgen receptor axis-targeted (ARAT) therapy: Treatments that target the androgen receptor or androgen production, such as abiraterone or enzalutamide, used to treat prostate cancer.
  • Prostate-specific antigen (PSA): A protein produced by the prostate gland; elevated levels may indicate prostate cancer or other prostate conditions.
  • Gigabecquerel (GBq): A unit of measurement for radioactivity, used to describe the dose of radioactive drugs like 177Lu-PNT2002.
  • Symptomatic skeletal-related event: A complication of bone metastases that can include bone pain, fractures, or spinal cord compression.

References

  1. http://clinicaltrials.eu/trial/study-on-treating-metastatic-castration-resistant-prostate-cancer-with-177lu-pnt2002-compared-to-abiraterone-or-enzalutamide-for-patients-after-hormonal-therapy/